Current immunosuppressive therapies target recipient T cell mediated adaptive immunity.
Donor treatment is a fascinating approach to prophylactically target Tx-IRI induced cell death and induction of allograft immunogenicity.
Anti-apoptotic and anti-necroptotic properties of simvastatin could be exploited in expansion of the donor pool and improvement of the transplant quality.